Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a biopharmaceutical company focusing on clinical-stage developments, announced new findings on soquelitinib, its leading ITK inhibitor program, at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases held from February 8-11, 2024.

The presentation highlighted Corvus' latest ITK inhibitor preclinical candidates, designed for precise modulation of T-cell activity targeting specific immunological conditions. These candidates show distinct biological properties aiming for more targeted inhibition of Th1, Th2, and/or Th17 cell functions. Th2 lymphocytes are associated with conditions like atopic dermatitis and asthma, Th17 cells with psoriasis and psoriatic arthritis, and Th1 immune response with diseases like rheumatoid arthritis.

Corvus, emphasized the company's pioneering work in ITK inhibition, particularly with soquelitinib. Miller noted, "Our research has led to next-generation inhibitors designed to precisely modulate specific T cell functions, potentially addressing a wide range of diseases."

Preclinical data demonstrated soquelitinib's effectiveness across six models of T cell-mediated inflammatory and immune conditions. The drug's impact on disease-associated cytokines, particularly those produced by Th2 and Th17 cells, showed promise in targeting cytokines like IL-4, IL-5, IL-13, and IL-17. These findings were presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, at the Keystone Symposia.

Soquelitinib, an orally administered investigational small molecule drug, selectively inhibits ITK, predominantly expressed in T cells and natural killer cells, thereby influencing immune function. Its immunological effects, termed Th1 skewing, are facilitated by its high selectivity for ITK. The drug has shown potential in controlling T cell differentiation, enhancing immune responses to tumors, and preventing T cell exhaustion, making it a promising candidate for cancer immunotherapy and autoimmune diseases.

Overall, Corvus' advancements in ITK inhibition, particularly through soquelitinib and next-generation inhibitors, hold significant promise for addressing a spectrum of diseases by modulating T cell responses with precision.

 

Source: globenewswire.com

Report Abuse